Co-Diagnostics, Inc. (CODX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

4.9900

+0.0200

(+0.40%)

At close: 04:00PM EDT

5.0700

+0.08

(+1.60%)

After hours:

07:59PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Inside Bar (Bearish)

View all chart patterns

Performance Outlook

Previous Close	4.9700
Open	5.0600
Bid	3.6600 x 2200
Ask	5.0200 x 800
Day's Range	4.9000 - 5.1917
52 Week Range	3.6600 - 11.8200
Volume	210,985
Avg. Volume	352,204

Market Cap	169.599M
Beta (5Y Monthly)	-1.14
PE Ratio (TTM)	3.80
EPS (TTM)	1.3120
Earnings Date	Aug 10, 2022 - Aug 15, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	18.33

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Undervalued

138% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for CODX

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Co-Diagnostics, Inc.
VIR: Raising target price to $24.00VIR BIOTECHNOLOGY INC has an Investment Rating of HOLD; a target price of $24.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
Rating
Fair Value
Economic Moat
4 days agoArgus Research

All

PR Newswire
Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 2022 Global Investment Conference on May 23-26
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the H.C. Wainwright & Co. 2022 Global Investment Conference, being held in-person and virtually on May 23-26 in Miami, Florida.
- Biomea Fusion to Attend H.C. Wainwright Global Investment Conference
  GlobeNewswire
- Airgain® to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022
  Business Wire
PR Newswire
Co-Diagnostics Reports Solid First Quarter 2022 Financial Results
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the first quarter ended March 31, 2022.
Simply Wall St.
Investors in Co-Diagnostics (NASDAQ:CODX) have made a stellar return of 289% over the past three years
Co-Diagnostics, Inc. ( NASDAQ:CODX ) shareholders might understandably be very concerned that the share price has...